
Roche’s ‘Operational Excellence’ programme will see it cut 6% of its global workforce over the next two years. The initiative …
Roche has admitted it does not know when phase III trials of the investigational type II diabetes drug taspoglutide will …
Phase III results for Roche’s once-weekly injectable drug taspoglutide have shown a positive effect on reducing blood glucose compared with …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

